Index- P/E- EPS (ttm)-1.21 Insider Own1.30% Shs Outstand32.05M Perf Week-1.45%
Market Cap84.90M Forward P/E- EPS next Y-1.43 Insider Trans23.88% Shs Float28.36M Perf Month42.63%
Income-33.60M PEG- EPS next Q-0.59 Inst Own44.30% Short Float3.82% Perf Quarter44.92%
Sales1.80M P/S47.17 EPS this Y75.80% Inst Trans-0.37% Short Ratio7.71 Perf Half Y-47.58%
Book/sh1.21 P/B2.24 EPS next Y24.30% ROA-29.10% Target Price19.00 Perf Year-57.92%
Cash/sh- P/C- EPS next 5Y- ROE-89.60% 52W Range1.70 - 8.10 Perf YTD-55.57%
Dividend- P/FCF- EPS past 5Y39.80% ROI-74.00% 52W High-66.54% Beta2.06
Dividend %- Quick Ratio7.80 Sales past 5Y119.70% Gross Margin77.20% 52W Low59.41% ATR0.18
Employees56 Current Ratio7.90 Sales Q/Q-94.20% Oper. Margin- RSI (14)66.20 Volatility6.93% 9.15%
OptionableYes Debt/Eq1.14 EPS Q/Q6.20% Profit Margin- Rel Volume0.59 Prev Close2.69
ShortableYes LT Debt/Eq1.14 EarningsMay 12 BMO Payout- Avg Volume140.42K Price2.71
Recom1.70 SMA2014.78% SMA5028.69% SMA200-33.67% Volume83,218 Change0.74%
Jan-22-21Initiated Guggenheim Buy $25
Jan-06-21Initiated Cantor Fitzgerald Overweight $30
Jul-11-18Upgrade Needham Hold → Buy $5
Jun-27-18Initiated Maxim Group Buy $6
Oct-24-17Initiated Guggenheim Buy $6
Jul-10-17Initiated ROTH Capital Buy $8.50
May-09-17Downgrade Needham Buy → Hold
Mar-03-17Reiterated RBC Capital Mkts Outperform $15 → $11
Oct-20-16Initiated H.C. Wainwright Buy $14
Oct-07-16Upgrade WBB Securities Buy → Strong Buy $8
Oct-03-16Resumed Brean Capital Buy
Aug-17-16Initiated Guggenheim Buy $15
Aug-09-16Upgrade WBB Securities Speculative Buy → Buy $8
Aug-09-16Reiterated Needham Buy $16 → $10
Mar-28-16Initiated Brean Capital Buy $16
Dec-29-15Initiated WBB Securities Strong Buy $8
Dec-29-15Initiated WBB Securities Speculative Buy $8
Nov-16-15Reiterated RBC Capital Mkts Outperform $18 → $17
Jun-10-15Initiated Needham Buy $16
May-29-14Initiated RBC Capital Mkts Outperform $17
Aug-09-22 08:30AM  
Aug-04-22 08:30AM  
Aug-01-22 08:30AM  
Jul-19-22 08:30AM  
Jul-14-22 08:30AM  
Jun-29-22 07:06AM  
Jun-23-22 08:30AM  
Jun-08-22 08:30AM  
Jun-03-22 04:05PM  
May-20-22 08:30AM  
May-12-22 08:35AM  
May-10-22 08:30AM  
May-05-22 08:30AM  
May-04-22 08:30AM  
Apr-30-22 08:55AM  
Apr-27-22 08:30AM  
Apr-26-22 05:18PM  
Apr-22-22 08:15AM  
Apr-21-22 04:01PM  
Apr-20-22 08:30AM  
Apr-19-22 08:30AM  
Apr-09-22 08:03AM  
Apr-04-22 09:59AM  
Mar-31-22 01:37PM  
Mar-29-22 08:15AM  
Mar-24-22 08:30AM  
Mar-08-22 08:30AM  
Mar-04-22 05:00PM  
Mar-02-22 08:30AM  
Feb-13-22 07:43AM  
Feb-10-22 07:36AM  
Feb-03-22 04:15PM  
Jan-20-22 10:13AM  
Jan-06-22 01:03PM  
Dec-22-21 08:30AM  
Dec-20-21 08:30AM  
Dec-15-21 08:30AM  
Dec-06-21 07:00AM  
Dec-03-21 04:30PM  
Dec-01-21 10:37AM  
Nov-29-21 08:30AM  
Nov-23-21 08:30AM  
Nov-18-21 05:18PM  
Nov-10-21 10:15AM  
Nov-09-21 08:30AM  
Nov-03-21 08:30AM  
Oct-21-21 08:30AM  
Oct-13-21 08:30AM  
Oct-11-21 08:30AM  
Oct-07-21 08:00AM  
Sep-30-21 08:00AM  
Sep-29-21 08:30AM  
Sep-23-21 08:30AM  
Sep-22-21 08:30AM  
Sep-20-21 11:38AM  
Sep-13-21 08:30AM  
Sep-08-21 08:30AM  
Aug-16-21 08:00AM  
Aug-13-21 05:15AM  
Aug-05-21 08:00AM  
Aug-02-21 05:00PM  
Jul-29-21 08:00AM  
Jul-12-21 08:00AM  
Jul-07-21 08:30AM  
Jul-02-21 04:01PM  
Jun-23-21 08:30AM  
Jun-22-21 09:48PM  
Jun-11-21 08:30AM  
Jun-09-21 08:30AM  
Jun-08-21 11:07AM  
Jun-02-21 07:30AM  
May-17-21 08:30AM  
May-14-21 08:30AM  
May-11-21 08:30AM  
Apr-30-21 08:00AM  
Apr-20-21 08:00AM  
Apr-12-21 09:21AM  
Mar-29-21 08:20AM  
Mar-02-21 07:30AM  
Feb-25-21 04:15PM  
Feb-17-21 10:04AM  
Feb-09-21 07:30AM  
Dec-27-20 11:20PM  
Dec-23-20 11:35AM  
Dec-22-20 08:00AM  
Dec-17-20 09:29AM  
Dec-16-20 04:21PM  
Dec-10-20 08:00AM  
Dec-07-20 08:00AM  
Nov-27-20 02:36PM  
Nov-24-20 09:35AM  
Nov-09-20 02:21PM  
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Taglietti MarcoChief Executive OfficerApr 26Buy3.0075,000225,000272,068Apr 28 07:25 AM
Sukenick ScottGeneral CounselApr 26Buy3.003,50010,50053,499Apr 28 07:24 AM